Swiss-based computational biology firm Genedata has established a subsidiary, Genedata KK, in Japan. The new offices in Tokyo’s Shinagawa district pave the way for a full professional services base in Japan, from which to provide local support for life sciences research with a focus on pharmaceutical research.
Japan is becoming an important global player in pharmaceutical research and development. Over the past few years, major Japanese pharmaceutical companies have expanded their research activities in the Asia region and beyond.
This has created demand for enterprise-level computational solutions for life sciences and drug discovery research. Genedata KK aims to satisfy this demand and to enable expansion of the company’s existing collaborations in Japan.
Each of Genedata’s international subsidiaries delivers computational support according to a proven collaborative framework. Genedata’s professional services points in the US, Europe and now Asia, ensure the smooth operation and evolution of its products and services.
Genedata has already attracted experienced people to the new subsidiary. The growing team, headed by Dr. Frank Staubli, brings broad knowledge and experience of the bioinformatics business in Japan. This has helped Genedata to maneuver into focused business areas, such as screening analysis and biomarker discovery as applied to toxicogenomics.
With more than five years experience providing support for drug discovery research on a global scale, Genedata has tailored its products and services for use in enterprise-wide and multi-site contexts. “We aim to help global research enterprises to bring together the best aspects of their research cultures,” explained Genedata CEO Dr. Othmar Pfannes.